Back to Results

Prurigo Nodularis


Title A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Therapeutic Area Prurigo Nodularis
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Gender All
Contact Nicole Dumont
617 636 7462
ndonovan1@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT04501666

Overview

Evaluate Safety and Efficacy of Nemolizumab in subject with Prurigo Nodularis

Study Details

Inclusion Criteria

  • Clinical diagnosis of PN for at least 6 months
  • PN lesions on upper limbs, trunk and/or lower limbs
  • At least 20 nodules on the entire body with bilateral distribution.

Exclusion Criteria

  • Body weight less than 30 kg (66 lbs)
  • Chronic itching from another active condition other than PN
  • Unilateral lesions of PN.

Study Requirements

7 visits over 28 weeks.